Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, 2C-T-7, LSD +2 moreDOI, 2C-T-7, LSD, psilocybin, mescaline show less
DPT
N,N-dipropyltryptamine
DPT (N,N-dipropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is a close structural analog of DMT, yet is orally active without a monoamine oxidase inhibitor. It activates serotonin receptors and simultaneously floods the brain with stored serotonin[1][2] — a dual mechanism shared by no other classical psychedelic.
DPT (N,N-dipropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is a close structural analog of DMT, distinguished by longer alkyl chains that allow oral activity without an monoamine oxidase inhibitor. DPT is a 5-HT₂A receptor agonist[1] that also releases serotonin through the SERT,[2] producing its effects through a dual mechanism shared by no other classical psychedelic.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, 2C-T-7, LSD +2 moreDOI, 2C-T-7, LSD, psilocybin, mescaline show less
DPT was first synthesized in the early 1950s during a systematic study of tryptamine compounds.[3] Controlled clinical trials followed in the 1970s, using DPT to treat alcoholism and end-of-life psychological distress.[4][5] It remains federally unscheduled in the United States and has reappeared on research chemical markets, with forensic identification confirmed as recently as March 2025.[6]
Subjective effects include geometric visual patterns, emotional warmth, a dissolving sense of self, deep introspective states, and heightened interpersonal connection. The experience blends classical psychedelic hallucination with empathogenic openness — clinical investigators consistently noted both qualities together,[4] distinguishing DPT from more purely visionary substances. Anxiety, nausea, and disorientation are characteristic unsought effects.
DPT does not produce physical dependence, and no pharmacological lethal dose has been established.[7] The primary risks are seizure at high doses and a life-threatening reaction when combined with MAO inhibitors or antidepressants, which amplify DPT's serotonin release to toxic levels.safety citation needed No human pharmacokinetic studies exist — understanding rests on 1970s clinical trials, animal studies, and a single case report.
History[edit]
Discovery
DPT was first synthesized in the early 1950s during a systematic exploration of tryptamine analogs.[3] Animal testing confirmed pharmacological activity in 1954,[8] and human psychedelic properties were established during the 1960s.[9] It first appeared as a designer drug by 1968.
Clinical research
The only controlled clinical studies of DPT were conducted at the Maryland Psychiatric Research Center between 1973 and 1980. Researchers including Stanislav Grof, Richard Soskin, and William Richards used DPT within structured therapeutic sessions to treat alcoholism and end-of-life psychological distress.[4][5] No clinical trials have been conducted since.
Regulatory history and modern re-emergence
DPT remains federally unscheduled in the United States as of 2026. The DEA proposed scheduling it in January 2022 but withdrew the proposal that July. It has reappeared on research chemical markets, with forensic identification confirmed as recently as March 2025.[6]
The name dipropyltryptamine describes the compound's structure directly: two n-propyl chains on the tryptamine nitrogen. It circulates almost exclusively under the abbreviation DPT in both research literature and drug culture, with no widely established street names.
Chemistry[edit]
N,N-Dipropyltryptamine belongs to the substituted tryptamine family, sharing the indole-ethylamine backbone found in DMT, psilocin, and serotonin itself. Its molecular formula is C₁₆H₂₄N₂ (244.37 g/mol).
DPT differs from DMT only in that two n-propyl groups replace DMT's two methyl groups at the nitrogen — a change that makes DPT more resistant to enzymatic breakdown and more lipophilic,[11] enabling oral activity without a monoamine oxidase inhibitor. DPT contains no stereocenters and has not been found to occur in any living organism.[8]
Pharmacology[edit]
Mechanism of action
DPT produces its psychedelic effects primarily by activating serotonin receptors in the brain.[1] Blocking those receptors completely eliminates DPT's behavioral effects — confirmed across mice, rats, and primates.[12][13][14]
DPT also enters serotonin-releasing neurons through the SERT and displaces stored serotonin into the synapse[2] — a mechanism more typical of MDMA than classical psychedelics. This dual action — receptor activation plus serotonin release — places DPT pharmacologically between purely visionary psychedelics and empathogen-type drugs.[15]
Pharmacokinetics
No human pharmacokinetic studies have been published for DPT. The oral dose required to produce effects is far higher than the intramuscular dose used in clinical studies,[16][4][5] indicating the liver breaks down a substantial fraction before it reaches the brain. Effects last roughly 20 minutes when smoked, 3–5 hours when insufflated, and 2–4 hours when taken orally.[16]
Neuroscience[edit]
Where it acts
No direct human brain imaging studies of DPT have been published. Based on its confirmed serotonin receptor activation, DPT is expected to act on prefrontal cortex neurons that filter incoming sensory and cognitive signals — particularly the network involved in self-referential thought.
DPT's serotonin release through the transporter[2] adds a neurochemical dimension absent in purely receptor-driven psychedelics like DMT. This flood of synaptic serotonin likely contributes to the empathogenic quality — heightened emotional expressiveness and deepened interpersonal connection — consistently documented in clinical settings.[4]
Why it matters
Current neuroscientific models predict that DPT's serotonin receptor activation temporarily loosens the brain's tendency to filter experience through prior expectations, allowing suppressed emotional and sensory information to surface more freely. The profound self-exploration and emotional breakthroughs documented in clinical studies[5] fit this framework well.
DPT's dose-dependent seizure effects remain mechanistically unexplained. At low doses it prevents seizures; at higher doses it triggers them — and neither serotonin receptor blockade nor sigma-1 receptor blockade prevents the anticonvulsant effect.[1]
Subjective Effects[edit]
DPT blends the visual intensity of a classical psychedelic with a warmth and emotional openness more typical of empathogens.[2] The two qualities coexist rather than alternate — vivid color and pattern arrive alongside a genuine softening of emotional distance. The resulting character is simultaneously visionary and intimate.
DPT sits between DMT and MDMA in felt character: more emotionally textured than DMT's raw visionary intensity, more hallucinatory than MDMA's warmth.[15] Compared to psilocybin, the body feel is heavier and the empathogenic quality more pronounced.[4]
First synthesized in the early 1950s during systematic exploration of tryptamine analogs,[3] DPT was the subject of controlled clinical trials for alcoholism and end-of-life distress at the Maryland Psychiatric Research Center between 1973 and 1980.[4][5] It remains federally unscheduled in the United States and has resurfaced on research chemical markets, with forensic identification confirmed as recently as March 2025.[6]
Subjective effects include geometric visual patterns, enhanced emotional expressiveness, ego dissolution, and deep introspective states. The experience blends vivid hallucinatory content with an empathogenic warmth — clinical investigators consistently described heightened emotional openness and interpersonal connection alongside classical psychedelic phenomena.[4] Anxiety, nausea, and disorientation are characteristic unsought effects.
DPT does not produce physical dependence, and no direct pharmacological lethal dose has been established — the single published fatality involved aspiration following a seizure, not confirmed overdose.[7] The primary acute risk is dose-dependent seizure potential: animal data show a narrow transition from anticonvulsant to proconvulsant effects,[1] and the dual serotonergic mechanism creates serious theoretical interaction risk with drugs that increase synaptic serotonin.safety citation needed No human pharmacokinetic studies have been published; the current understanding rests on a small clinical literature from the 1970s, animal pharmacology, and forensic case data.
History[edit]
Discovery
DPT was first synthesized in the early 1950s as part of a systematic campaign to characterize N,N-dialkyl tryptamine analogs.[3] Animal testing confirmed pharmacological activity in 1954,[8] and human psychedelic properties were established during the 1960s.[9] DPT was encountered as a novel designer drug as early as 1968.
Clinical research
The only controlled clinical studies of DPT were conducted at the Maryland Psychiatric Research Center between 1973 and 1980 by a team including Stanislav Grof, Richard Soskin, and William Richards. A study of 103 male alcoholic patients used low-dose sessions (15–45 mg) for therapeutic preparation followed by a single high-dose session (75–265 mg), with therapist-rated improvements in emotional expressiveness and self-exploration.[4] A later pilot project administered DPT (75–227.5 mg) to 30 cancer patients experiencing psychological distress, targeting "peak experiences" as a therapeutic endpoint.[5] No clinical trials have been conducted since.
Regulatory history and modern re-emergence
DPT remains federally unscheduled in the United States as of 2026. The DEA proposed scheduling several tryptamines in January 2022 but withdrew the proposal that July. DPT has reappeared on research chemical markets as a novel psychoactive substance; the Centre for Forensic Science Research and Education first identified it in forensic casework in March 2025.[6]
The name dipropyltryptamine describes the compound's structure directly: two n-propyl chains on the tryptamine nitrogen. It circulates almost exclusively under the abbreviation DPT in both research literature and drug culture, with no widely established street names.
Chemistry[edit]
Structure
N,N-Dipropyltryptamine belongs to the substituted tryptamine family, sharing the indole-ethylamine backbone common to DMT, psilocin, and endogenous serotonin. DPT differs from DMT solely at the amine nitrogen: two n-propyl groups replace DMT's two methyl groups.
This increased bulk at the nitrogen reduces susceptibility to monoamine oxidase breakdown and increases lipophilicity,[11] which is why DPT is orally active without an MAO inhibitor — a key distinction from DMT. DPT contains no stereocenters and is achiral.[8]
| Molecular formula | C₁₆H₂₄N₂ |
| Molecular weight | 244.37 g/mol |
Physical properties
The hydrochloride salt forms a white crystalline solid with a melting point of 178–179°C.[12] The free base exists as an oily liquid at room temperature.[6] No published data characterize solubility, degradation pathways, or long-term stability.
DPT is purely synthetic and has not been found to occur naturally in humans or other organisms.[8]
Structure-activity relationships
The N,N-dipropyl substitution is DPT's defining structural feature. Lengthening DMT's methyl chains to propyl chains substantially increases the molecule's resistance to MAO-mediated deamination, enabling oral bioavailability without enzyme inhibition. The longer chains also raise lipophilicity (XLogP 4.3 vs. ~2.0 for DMT),[11] suggesting efficient passage across the blood-brain barrier. These two changes — metabolic resistance and lipophilicity — account for DPT's longer duration and oral activity compared to DMT.
Pharmacology[edit]
Mechanism of action
DPT produces its psychedelic effects primarily through activation of the 5-HT₂A serotonin receptor.[1] This has been confirmed across multiple species: the selective 5-HT₂A blocker MDL100907 completely abolishes DPT's behavioral effects in mice, rats, and primates.[13][14][15]
DPT also partially activates the 5-HT₁A serotonin receptor.[1] This secondary action is normally overshadowed by the dominant 5-HT₂A effects but becomes apparent when 5-HT₂A is pharmacologically blocked.[14]
What sets DPT apart from other classical psychedelics is its action at the SERT (SERT). DPT enters serotonin neurons through this transporter and displaces stored serotonin into the synapse[2] — a mechanism more typically associated with MDMA than with psychedelics like DMT. This dual action — direct receptor activation plus transporter-mediated serotonin release — places DPT pharmacologically between the purely receptor-driven psychedelics and the predominantly releaser-driven empathogens.[16]
DPT also enters intracellular vesicles via the vesicular monoamine transporter (VMAT2).[2] An unidentified anticonvulsant mechanism — independent of serotonin receptors and sigma-1 receptors — has been observed at lower doses in animal models.[1]
Pharmacokinetics
No human pharmacokinetic studies have been published for DPT. Bioavailability, plasma half-life, and specific metabolic pathways remain uncharacterized.
Oral doses of 100–250 mg produce psychedelic effects,[12] compared with intramuscular doses of roughly 15–60 mg used in clinical studies,[4][5] implying substantial first-pass metabolism by the liver. DPT is presumed to undergo deamination by MAO-A and N-dealkylation of its propyl chains, but no CYP enzyme data exist.
DPT is moderately lipophilic,[11] suggesting efficient brain penetration. Oral effects last 2–4 hours; smoked effects persist roughly 20 minutes; insufflated effects last 3–5 hours.[12] The oral duration is intermediate between smoked DMT and oral psilocybin.
Neuroscience[edit]
Where it acts
No direct neuroimaging or electrophysiology studies of DPT have been published. Based on its confirmed 5-HT₂A agonism, DPT is expected to act on deep-layer pyramidal neurons in the prefrontal cortex, disrupting the brain's default filtering of sensory and cognitive input — particularly the default mode network.
DPT's concurrent serotonin release through the SERT[2] adds a neurochemical dimension absent in purely receptor-driven psychedelics like DMT. This flood of synaptic serotonin may contribute to the empathogenic qualities — enhanced emotional expressiveness and deepened interpersonal connection — consistently documented in clinical settings.[4]
Why it matters
The relaxed beliefs under psychedelics (REBUS) model predicts that DPT's 5-HT₂A agonism would temporarily loosen the brain's prior expectations, allowing bottom-up sensory and emotional information to surface more freely. The clinical reports of profound self-exploration and "peak experiences"[5] fit this framework.
DPT's 5-HT₂A activation also predicts neuroplasticity-promoting effects through BDNF and related signaling pathways, but no direct neuroplasticity assays have been published for DPT.
DPT raises several unresolved questions. The mechanism behind its dose-dependent seizure effects — anticonvulsant at low doses, proconvulsant at high doses — remains unknown, since neither serotonin receptor nor sigma-1 receptor blockade prevents the anticonvulsant effect.[1]
Subjective Effects[edit]
DPT's dual pharmacology — direct 5-HT₂A agonism layered with transporter-mediated serotonin release[2] — produces an experience that sits between the purely visionary character of DMT and the emotional warmth of MDMA. At lower doses the empathogenic register dominates: heightened emotional openness, deepened self-reflection, and an interpersonal warmth that clinical investigators consistently noted.[4] At higher doses, vivid hallucinatory content and profound alterations of consciousness take the foreground, with emotional depth persisting as an undertone. Set and setting are particularly potent modulators given the emotional resonance DPT reliably produces.
Compared to DMT, DPT trades raw visionary intensity for a more emotionally textured arc; compared to psilocybin, the body feel is heavier and the empathogenic quality more pronounced. Route of administration dramatically shapes the experience — smoked DPT is a brief, intense immersion, while oral administration yields a more gradual, therapeutically tractable trajectory.[16]
Effect Grid
At common oral doses (~100–175 mg), the full psychedelic experience emerges. Visual hallucinations include bright bursts of light, geometric patterning overlaying surfaces, and tunnel-like visions. Enhanced emotional expressiveness and deepened self-exploration become prominent — the therapeutic qualities leveraged in the 1970s MPRC clinical studies. Time distortion is significant. Thought acceleration and novel associative thinking are typical.
Physically, pupil dilation is pronounced. Cardiovascular stimulation (elevated heart rate, blood pressure) is expected as a class effect. Body load ranges from a warm, diffuse sensation to noticeable muscular tension. Nausea is possible during onset.
Sleep is not possible during the active phase. Full commitment time is 4–6 hours including aftereffects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Ganzfeld effect · Environmental patterning · Symmetrical texture repetition · Tracers · Color enhancement · Visual morphing · After-images · Visual haze / noise · Music enhancement · Spatial disorientation · Auditory distortion · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Visual melting · Visual magnification · Vestibular distortion · Auditory misinterpretation · Peripheral vision distortion · Proprioceptive distortion · Sound sensitivity · Touch enhancement · Visual diffraction · Synesthesia · Dreaming enhancement · Peripheral misidentification · Visual acuity enhancement · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Auditory hallucinations · Visual scenery slicing · Object activation · Perspective hallucinations · Shadow people · Visual flipping · Olfactory hallucination · Persisting hallucinations
Tracers · Color enhancement · Visual morphing · After-images · Visual haze / noise · Music enhancement · Spatial disorientation · Auditory distortion · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Visual melting · Visual magnification · Vestibular distortion · Auditory misinterpretation · Peripheral vision distortion · Proprioceptive distortion · Sound sensitivity · Touch enhancement · Visual diffraction · Synesthesia · Dreaming enhancement · Peripheral misidentification · Visual acuity enhancement · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Auditory hallucinations · Visual scenery slicing · Object activation · Perspective hallucinations · Shadow people · Visual flipping · Olfactory hallucination · Persisting hallucinations
Wakefulness · Body high · Body schema distortion · Muscle tension · Stimulation · Physical fatigue · Vibrations / buzzing · Nausea · Appetite suppression · Dizziness · Heart rate perception changes · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Insomnia · Involuntary body movements · Kundalini-like energy · Restlessness · Tactile euphoria · Temperature dysregulation · Trembling · Dehydration sensation · Headache · Bodily lightness · Laughter fits · Nystagmus (eye wobbles) · Respiratory stimulation · Vasoconstriction · Yawning · Sexual arousal enhancement · Bruxism · Diarrhea · Muscle relaxation · Nasal congestion · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Muscle tension · Stimulation · Physical fatigue · Vibrations / buzzing · Nausea · Appetite suppression · Dizziness · Heart rate perception changes · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Insomnia · Involuntary body movements · Kundalini-like energy · Restlessness · Tactile euphoria · Trembling · Dehydration sensation · Headache · Bodily lightness · Laughter fits · Nystagmus (eye wobbles) · Respiratory stimulation · Vasoconstriction · Yawning · Sexual arousal enhancement · Bruxism · Diarrhea · Muscle relaxation · Nasal congestion · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Confusion · Thought disorganization · Cognitive impairment · Focus suppression · Introspection enhancement · Pattern recognition enhancement · Language suppression · Multiple thought streams · Thought loops · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Information processing suppression · Openness enhancement · Thought connectivity · Cognitive euphoria · Cognitive flexibility · Increased nature relatedness · Memory fragmentation · Motivation suppression · Thought acceleration · Creativity enhancement · Memory replays · Synchronicity · Humor enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Information processing enhancement · Amnesia · Delirium · Delusions
Focus suppression · Introspection enhancement · Pattern recognition enhancement · Language suppression · Multiple thought streams · Thought loops · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Information processing suppression · Openness enhancement · Thought connectivity · Cognitive euphoria · Cognitive flexibility · Increased nature relatedness · Memory fragmentation · Motivation suppression · Thought acceleration · Creativity enhancement · Memory replays · Synchronicity · Humor enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Information processing enhancement · Delirium · Delusions
Emotional lability · Simultaneous emotions · Catharsis · Euphoria · Empathy enhancement · Irritability
Empathy enhancement · Irritability
Social disconnection · Sociability suppression · Disinhibition · Automaticity · Ego inflation · Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Ego inflation · Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Transpersonal visions · Death-rebirth sequence · Near-death experience · Non-dual awareness · Cessation · Transpersonal memory access · Voidness
Cessation · Transpersonal memory access · Voidness
Timeline
First alerts emerge as subtle mood shift and mild perceptual brightening. A gentle body awareness develops, centered in the abdomen.
Visual effects begin — color saturation increases, surfaces may breathe or shift. Emotional sensitivity heightens noticeably. Mild nausea is possible during this phase.
Full psychedelic intensity: vivid geometric hallucinations, bright bursts of light, tunnel-like visions. Emotional depth and self-exploration reach maximum. Time distortion is pronounced.
Visual effects gradually recede. Emotional intensity softens but introspective thinking often continues. Physical tension releases progressively.
Residual mood elevation, enhanced emotional openness, and mild perceptual sensitivity may persist. Cognitive integration of the experience often continues during this phase.
⚠ Do not drive or operate machinery for at least 6 hours after ingestion, as residual perceptual and cognitive effects may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · 2C-T-7 · LSD
Toxicity
No lethal dose has been established for DPT in any species. The toxic threshold in humans is unknown.
Fatal case
The one published fatality involved a 20-year-old male who insufflated an unknown quantity of DPT.[7] He progressed from visual hallucinations to collapse, seizure, and vomiting within roughly two hours, and died 21 hours later despite advanced life support.
Seizure risk
DPT has dose-dependent effects on seizure threshold.[1] In animal models, low doses prevent seizures; at roughly double that dose, DPT itself triggers them. The single fatal case involved a seizure approximately two hours after insufflation,[7] consistent with high-dose proconvulsant risk.
Heart and circulation
No DPT-specific cardiovascular data exist. As a drug that activates serotonin receptors and releases serotonin into the synapse, DPT is expected to raise blood pressure and heart rate.safety citation needed
Psychological risks
Acute anxiety and psychological distress are predictable risks, consistent with all serotonergic psychedelics. Clinical studies reported low rates of serious adverse effects in supervised settings.[4][5]
Anxiety is a documented effect.[6] People with a personal or family history of psychosis may be at higher risk for triggering psychotic episodes — a risk shared by the psychedelic class.safety citation needed No DPT-specific data on lasting perceptual disturbances exist; class-level risk is acknowledged.[6]
Tolerance & dependence
DPT does not build tolerance to its own effects in animal studies — an unusual finding that contrasts sharply with other psychedelic classes.[17] Animals tolerant to other psychedelics do show reduced response to DPT, indicating one-way cross-tolerance.[17]
DPT is not considered habit-forming.[12] No dependence, self-administration, or withdrawal data have been published.
Drug Interactions
DPT activates serotonin receptors directly and simultaneously releases stored serotonin into the synapse. Any drug that adds more serotonin to the system stacks on top of this dual effect.
MAO inhibitors are the most dangerous combination — they block the enzyme that breaks down serotonin, so DPT's serotonin release produces toxic concentrations that can cause a life-threatening overheating and seizure response.safety citation needed SSRIs and SNRIs block serotonin clearance and add to the same overload.safety citation needed Other serotonergic psychedelics produce additive effects in animal models,[18] and drugs that block a secondary serotonin receptor may intensify DPT's hallucinogenic effects.[12]
Contraindications
7 knownBased on DPT's pharmacology and the available evidence, the following conditions contraindicate use:
- Seizure disorders — DPT is proconvulsant at high doses in animals[1] and the single fatal case involved seizure[7]
- Concurrent MAO inhibitor use — the combination creates pharmacological grounds for life-threatening serotonin overloadsafety citation needed
- Personal or family history of psychotic disorders or bipolar disorder — class-level risk from serotonin receptor activationsafety citation needed
- Uncontrolled high blood pressure or heart conditions — expected cardiovascular stimulationsafety citation needed
- Pregnancy and breastfeeding — no safety data exist
Harm Reduction[edit]
Forms & Identification
DPT circulates as both the hydrochloride salt (white crystalline solid)[16] and the free base (oily liquid).[6] Both are visually indistinguishable from many other compounds, so reagent testing is necessary. A positive test confirms identity — not purity, potency, or safety.
Weigh every dose on a milligram-precision scale. No human pharmacokinetic data exist, meaning dose-response relationships are poorly understood even for accurately identified material.
Guidelines
- Test all material with appropriate reagent kits before use
- Use a milligram-precision scale for every dose — never estimate
- Start with a low dose and wait for full onset before considering redosing
- Have a sober, trusted companion present, especially at higher doses
- Choose a physically safe, comfortable environment with access to water and fresh air
- Avoid eating heavily for 2–3 hours before an oral dose to reduce nausea
- Clear the schedule for the full duration plus several hours of recovery
- Do not combine with monoamine oxidase inhibitors, SSRIs, SNRIs, or other serotonergic drugs
Set & Setting
DPT's empathogenic-psychedelic blend makes it unusually sensitive to emotional context. Clinical researchers administered it only within structured therapeutic frameworks with extensive preparation,[4] and the outcomes reflected how much set and setting mattered.
A calm, familiar environment with a trusted sober companion is important, particularly at higher doses. Avoid high-stakes situations and unresolved interpersonal conflict. Smoked and insufflated routes produce rapid onset that can be disorienting without preparation.
Aftercare & integration. DPT's empathogenic qualities frequently surface emotionally charged material. Allow time for quiet reflection in the hours and days following a session. Journaling while details remain fresh can help organize insights.
The clinical researchers who worked with DPT embedded it in a psychotherapeutic framework for good reason — the emotional content it produces benefits from structured processing. If the experience raised difficult emotions or memories, consider speaking with a therapist experienced in psychedelic integration. Peer integration circles can also provide support.
Resume normal obligations only when feeling grounded. Avoid major decisions in the immediate aftermath.
Recovery & Support
DPT is not considered physically addictive and does not produce dependence or withdrawal. Problematic patterns of use with any psychedelic can still develop — particularly as a means of avoiding difficult emotions rather than processing them.
If use has become compulsive or is interfering with daily functioning, support is available through psychedelic-informed therapists, harm reduction organizations such as the Fireside Project (62-FIRESIDE), and peer support communities. SAMHSA's National Helpline (1-800-662-4357) provides free referrals to local treatment services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The transition from uncomfortable to dangerous centers on seizure. Warning signs include sudden muscle rigidity, rhythmic jerking, loss of consciousness, or inability to respond. Severe confusion, chest pain, or extremely rapid heartbeat also warrant immediate help.
Immediate steps:
- Call emergency services immediately if seizure, loss of consciousness, or breathing difficulty occurs
- If the person is seizing, clear the area around them — do not restrain them or place anything in their mouth
- After a seizure stops, place the person in the recovery position (on their side) to prevent aspiration if vomiting occurs
- Do not induce vomiting
- Stay with the person and monitor breathing until help arrives
What to tell the dispatcher: Name the substance (DPT / dipropyltryptamine), the approximate amount and route if known, the time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for DPT or any serotonergic psychedelic. Treatment is supportive.
Legal Status[edit]
DPT is federally unscheduled in the United States and Canada, while controlled in the United Kingdom, several EU member states, Japan, and New Zealand.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | Not on DEA Schedule I–V. Federal Analogue Act may apply if intended for human consumption. DEA proposed scheduling in January 2022, withdrew July 2022[19] |
| United States (Florida) | Schedule I | Illegal to buy, sell, or possess[19] |
| United States (Maine) | Schedule X | Equivalent to Schedule I; illegal[19] |
| Canada | Unscheduled | Not specifically listed under Controlled Drugs and Substances Act as of 2025citation needed |
| United Kingdom | Class A | Controlled under Misuse of Drugs Act 1971; tryptamine clause covers compounds structurally derived from tryptamine with alkyl substitutions[19] |
| Portugal | Table II-A | Listed alongside MDMA and LSD[19] |
| Belgium | Most restrictive category | Approximately equivalent to US Schedule II[19] |
| Greece | Controlled | Since February 18, 2003[19] |
| Japan | Designated Substance | Under Pharmaceutical Affairs Law; possession and sale prohibited[19] |
| Sweden | Controlled | Since January 26, 2016; manufacturing, trade, and possession prohibited[19] |
| New Zealand | Class C | As DMT analog under Misuse of Drugs Act[8] |
| Australia | Likely controlled (unconfirmed) | Not specifically confirmed as Schedule 9; likely covered as DMT analog under broad tryptamine provisionscitation needed |
Analog act considerations
In the United States, DPT's structural similarity to DMT (Schedule I) makes it potentially subject to the Federal Analogue Act, which treats structurally similar substances as equivalent when intended for human consumption.[19] DPT differs from DMT only in alkyl chain length — a difference likely within the scope of the structural similarity criterion.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · 2C-T-7 · LSD
Toxicity
No lethal dose has been established for DPT in any species. No therapeutic index can be calculated, and the threshold for toxic effects in humans is unknown.
Fatal case
The single published fatality involved a 20-year-old male who insufflated an unknown quantity of DPT.[7] The progression ran from visual hallucinations (10–15 minutes) through apathy (~30 minutes) to abdominal pain, collapse, seizure, and vomiting (~2 hours). Death occurred 21 hours post-consumption despite advanced life support.
Seizure risk
DPT has dose-dependent effects on seizure threshold.[1] In animal models, low doses completely prevent seizures; at roughly double that dose, DPT itself triggers seizures. The fatal human case involved a seizure at approximately 2 hours post-insufflation,[7] consistent with high-dose proconvulsant risk.
Heart and circulation
No DPT-specific cardiovascular data exist. As a serotonin agonist with serotonin-releasing properties, DPT is expected to raise blood pressure and heart rate.safety citation needed
Psychological risks
Acute psychological distress is a predictable risk, consistent with all serotonergic psychedelics. Clinical studies reported low rates of serious psychological adverse effects in supervised settings,[4][5] but specific adverse event rates are unavailable.
Anxiety has been documented in DPT effects profiles.[6] Precipitation of psychotic episodes in individuals with personal or family history of psychotic disorders is a class-level risk.safety citation needed No DPT-specific data on HPPD (HPPD) exist; class-level risk is acknowledged.[6]
Tolerance & dependence
DPT does not produce tolerance to its own effects in mice, contrasting sharply with phenethylamine psychedelics which rapidly develop tolerance.[17] Cross-tolerance from phenethylamine psychedelics to DPT does occur — animals tolerant to DOI show reduced response to DPT — but the reverse was not tested.[17]
DPT is not considered habit-forming, consistent with the psychedelic class as a whole.[13] No dependence, self-administration, or withdrawal data have been published.
Drug Interactions
DPT's dual serotonergic mechanism — direct receptor activation combined with serotonin release through the transporter — creates compounded risk with any drug that raises synaptic serotonin.
MAO inhibitors are the most dangerous predicted combination. DPT releases serotonin into the synapse; monoamine oxidase inhibition prevents that serotonin from being broken down, producing sustained toxic concentrations. Life-threatening serotonin syndrome is the expected outcome.safety citation needed
SSRIs, SNRIs, and tricyclic antidepressants add further serotonergic load through reuptake inhibitor, elevating serotonin syndrome risk when combined with DPT's dual mechanism.safety citation needed
Other 5-HT₂A agonists produce additive effects with DPT in animal models.[18] Drugs that block 5-HT₁A receptors may intensify DPT's hallucinogenic effects, while 5-HT₁A agonists may dampen them.[13]
No data exist on CYP enzyme interactions, making pharmacokinetic interaction prediction impossible.
Contraindications
7 knownSeizure disorders are contraindicated based on substance-specific evidence: DPT is proconvulsant at high doses in animals[1] and the single fatal case involved seizure.[7]
Concurrent MAO inhibitor use is an absolute contraindication. The combination of serotonin release and direct receptor activation creates clear pharmacological grounds for life-threatening serotonin syndrome.safety citation needed
Personal or family history of psychotic disorders or bipolar disorder is a standard class contraindication given 5-HT₂A agonism.safety citation needed
Heart conditions including uncontrolled high blood pressure are contraindicated based on expected serotonergic cardiovascular stimulation.safety citation needed
Pregnancy and breastfeeding — no safety data exist.
Harm Reduction[edit]
Forms & Identification
DPT circulates as both the hydrochloride salt (white crystalline powder) and the free base (oily liquid). Because it is visually indistinguishable from many other white powders, reagent testing matters — but identification is only the first step. The absence of human pharmacokinetic data means dose-response relationships are poorly understood, and even accurately identified material carries inherent uncertainty. Weigh doses with a milligram-precision scale; volumetric estimation is unreliable for any powdered tryptamine.
Guidelines
- Test all material with appropriate reagent kits before use
- Use a milligram-precision scale for every dose — never estimate
- Start with a low dose and wait for full onset before considering redosing
- Have a sober, trusted sitter present, especially at higher doses
- Choose a physically safe, comfortable environment with access to water and fresh air
- Avoid eating heavily for 2–3 hours before an oral dose to reduce nausea
- Clear your schedule for the full duration plus several hours of recovery
- Do not combine with monoamine oxidase inhibitors, SSRIs, SNRIs, or other serotonergic drugs
Set & Setting
DPT's empathogenic-psychedelic blend makes it unusually responsive to emotional context. Clinical researchers administered it within structured therapeutic frameworks with extensive preparation,[4] and the results reinforced that set and setting substantially shape the experience.
A calm, familiar environment with a trusted sitter is strongly recommended, particularly at higher doses. Avoid situations with high emotional stakes or interpersonal conflict. The relatively short oral duration (2–4 hours) is manageable, but insufflated and smoked routes produce rapid onset that can be disorienting without preparation.
Aftercare & integration. DPT's empathogenic qualities frequently surface emotionally charged material. In the hours and days following a session, allow time for quiet reflection. Journaling the experience while details remain fresh can help organize insights.
The clinical researchers who worked with DPT embedded it within a psychotherapeutic framework for good reason — the emotional content it produces benefits from structured processing. If the experience raised difficult emotions or memories, consider speaking with a therapist experienced in psychedelic integration. Peer integration circles and online communities can also provide support.
Resume normal obligations only when you feel grounded. Avoid making major life decisions in the immediate aftermath.
Recovery & Support
DPT is not considered physically addictive and does not produce dependence or withdrawal. Problematic patterns of use with any psychedelic, however, can develop — particularly as a means of avoiding difficult emotions rather than processing them.
If use has become compulsive or is interfering with daily functioning, support is available through psychedelic-informed therapists, harm reduction organizations such as the Fireside Project (62-FIRESIDE), and peer support communities. SAMHSA's National Helpline (1-800-662-4357) provides free referrals to local treatment services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The transition from uncomfortable to dangerous with DPT centers on seizure. Warning signs include sudden muscle rigidity, rhythmic jerking, loss of consciousness, or inability to respond. Severe confusion, chest pain, or extremely rapid heartbeat also warrant immediate help.
Immediate steps:
- Call emergency services immediately if seizure, loss of consciousness, or breathing difficulty occurs
- If the person is seizing, clear the area around them — do not restrain them or place anything in their mouth
- After a seizure stops, place the person in the recovery position (on their side) to prevent aspiration if they vomit
- Do not induce vomiting
- Stay with the person and monitor breathing until help arrives
What to tell the dispatcher: Name the substance (DPT / dipropyltryptamine), the approximate amount and route if known, the time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for DPT or any serotonergic psychedelic. Treatment is supportive.
Legal Status[edit]
DPT occupies an unusual regulatory position: it remains federally unscheduled in the United States and Canada, while being controlled in the United Kingdom, several EU member states, Japan, and New Zealand. The Federal Analogue Act (21 U.S.C. §813) may apply to DPT in the United States if intended for human consumption, given its structural relationship to scheduled tryptamines. Two U.S. states have independently scheduled DPT.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | Not on DEA Schedule I–V. Federal Analogue Act may apply if intended for human consumption. DEA proposed scheduling in January 2022, withdrew July 2022[19] |
| United States (Florida) | Schedule I | Illegal to buy, sell, or possess[19] |
| United States (Maine) | Schedule X | Equivalent to Schedule I; illegal[19] |
| Canada | Unscheduled | Not specifically listed under Controlled Drugs and Substances Act as of 2025citation needed |
| United Kingdom | Class A | Controlled under Misuse of Drugs Act 1971; tryptamine clause covers compounds structurally derived from tryptamine with alkyl substitutions[19] |
| Portugal | Table II-A | Listed alongside MDMA and LSD[19] |
| Belgium | Most restrictive category | Approximately equivalent to US Schedule II[19] |
| Greece | Controlled | Since February 18, 2003[19] |
| Japan | Designated Substance | Under Pharmaceutical Affairs Law; possession and sale prohibited[19] |
| Sweden | Controlled | Since January 26, 2016; manufacturing, trade, and possession prohibited[19] |
| New Zealand | Class C | As DMT analog under Misuse of Drugs Act[8] |
| Australia | Likely controlled (unconfirmed) | Not specifically confirmed as Schedule 9; likely covered as DMT analog under broad tryptamine provisionscitation needed |
Analog act considerations
In the United States, DPT's structural relationship to DMT (Schedule I) makes it potentially subject to the Federal Analogue Act, which treats substances "substantially similar" to Schedule I/II compounds as equivalent when intended for human consumption. DPT differs from DMT only in N-alkyl chain length, which would likely satisfy the structural similarity criterion.[19]
Frequently asked questions
What is DPT?
DPT is a synthetic tryptamine psychedelic distinguished by dual 5-HT₂A agonism and SERT substrate activity. First synthesized in the early 1950s, it was studied in controlled clinical trials for alcoholism and cancer-related distress at the Maryland Psychiatric Research Center (1973–1980).
How long does DPT last?
Total duration by route of administration — Oral: 2 – 4 hours; Smoked: 20 – 30 min; Insufflated: 3 – 5 hours; Intramuscular: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for DPT?
Psychedex publishes a dosage table for DPT on this page covering these routes of administration: smoked, insufflated, oral, intramuscular. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with DPT?
The highest-severity documented interactions for DPT: MAOIs (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Dopamine agonists (Dangerous), DXM (Dangerous), GHB, Baclofen (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is DPT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for DPT: tolerance builds none; cross-tolerance develops with DOI, 2C-T-7, LSD, psilocybin, mescaline. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdCozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. — Journal of neural transmission doi:10.1007/s00702-009-0308-8
- [3]
- [4]
- [5]
- [6]
references
- [1]
- [2] ^abcdeCozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. — Journal of neural transmission doi:10.1007/s00702-009-0308-8
- [3]
- [4]
- [5]
- [6]